Lenvatinib is an effective treatment for refractory nasopharyngeal carcinoma harboring FGFR3-TACC fusion: a case report

Background: Molecular targeted therapy is a novel and effective approach to treat some advanced solid tumors. It may also be therapeutic therapy for nasopharyngeal carcinoma (NPC). Case presentation: Herein, we report a patient with refractory NPC who benefited from treatment with Lenvatinib based on the results of next generation sequencing (NGS), which revealed the presence of fibroblast growth factor receptor 3 (FGFR3) and transforming acidic coiled-coil-containing protein (TACC3) gene fusion. Conclusions: Genomic alteration analysis based on NGS may help patients with refractory NPC to find effective therapeutic targets.